Document is current
Any future updates will be listed below
-
Authors
Singh, Devesh
Brima, Yusuf
Levin, Fedor
Becker, Martin
Hiller, Bjarne
Hermann, Andreas
Villar-Munoz, Irene
Beichert, Lukas
Bernhardt, Alexander
Buerger, Katharina
Butryn, Michaela
Dechent, Peter
Düzel, Emrah
Ewers, Michael
Fliessbach, Klaus
Freiesleben, Silka D.
Glanz, Wenzel
Hetzer, Stefan
Janowitz, Daniel
Görß, Doreen
Kilimann, Ingo
Kimmich, Okka
Laske, Christoph
Levin, Johannes
Lohse, Andrea
Luesebrink, Falk
Munk, Matthias
Perneczky, Robert
Peters, Oliver
Preis, Lukas
Priller, Josef
Prudlo, Johannes
Prychynenko, Diana
Rauchmann, Boris S.
Rostamzadeh, Ayda
Roy-Kluth, Nina
Scheffler, Klaus
Schneider, Anja
Droste zu Senden, Louise
Schott, Björn H.
Spottke, Annika
Synofzik, Matthis
Wiltfang, Jens
Jessen, Frank
Weber, Marc-André
Teipel, Stefan J.
Dyrba, Martin
-
Funding
Funding for this research was provided by:
Deutsches Zentrum für Neurodegenerative Erkrankungen e.V. (DZNE) in der Helmholtz-Gemeinschaft
- License Information
-
More Information
Article History
Received: 9 May 2025
Accepted: 27 October 2025
First Online: 12 November 2025
Declarations
:
: S.Teipel: was serving on advisory boards of Eisai, Lilly, and GE Healthcare. He is member of the independent data safety and monitoring board of the study ENVISION (Biogen). A.Hermann: received honoraria for presentations and participation in advisory boards from Amylyx and IFT Pharma. He has received royalties from Elsevier Press and Kohlhammer. E.Duezel: Paid consultancy work and talks for Roche, Lilly, Eisai, Biogen, neotiv, and UCLC; Holds shares of neotiv. O.Peters: Paid consultancy work and talks for Biogen, Eisai, Grifols, Lilly, Noselab, Prinnovation, Schwabe, and Roche. J.Wiltfang: Paid consultancy and talks for Abbott, Actelion, Amgen, Beijing Yibai Science and Technology Ltd., Biogen, Boehringer Ingelheim, Gloryren, Immungenetics, Janssen Cilag, Lilly, Med Update GmbH, MSD Sharp & Dohme, Noselab, Pfizer, Roche, and Roboscreen; holds patents PCT/EP2011 001724 and PCT/EP 2015 052945 and also supported by an Ilidio Pinho professorship, iBiMED (UIDB/04501/2020) at the University of Aveiro, Portugal. J.Priller: serves on the TSC of the Sinapps2 study and holds patents on EPO variants. F.Jessen: received fees for consultation from Eli Lilly, Novartis, Roche, BioGene, MSD, Piramal, Janssen, and Lundbeck. M.Synofzik: received consultancy honoraria from Ionis, UCB, Prevail, Orphazyme, Servier, Reata, GenOrph, AviadoBio, Biohaven, Zevra, and Lilly, all unrelated to the present manuscript. J.Levin: speaker fees from Bayer Vital, Biogen, EISAI, TEVA, and Roche, consulting fees from Axon Neuroscience and Biogen, author fees from Thieme medical publishers. These financial interests caused no effects on the study design, data collection and analysis, decision to publish, or preparation of the manuscript. All other authors declare no competing interests.
